These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23412977)

  • 1. Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma.
    Wang H; Li YP; Chen JH; Yuan SF; Wang L; Zhang JL; Yao Q; Li NL; Bian JF; Fan J; Yi J; Ling R
    Tumour Biol; 2013 Jun; 34(3):1635-9. PubMed ID: 23412977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma.
    Dai W; Yao Y; Zhou Q; Sun CF
    PLoS One; 2014; 9(1):e87148. PubMed ID: 24466336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

  • 4. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics.
    Yang M; Liu YD; Wang YY; Liu TB; Ge TT; Lou G
    Tumour Biol; 2014 Feb; 35(2):929-34. PubMed ID: 23979981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer.
    Zhang Y; Yao L; Zhang X; Ji H; Wang L; Sun S; Pang D
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1245-53. PubMed ID: 21691749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer.
    Ning J; Zhang J; Liu W; Lang Y; Xue Y; Xu S
    Eur J Histochem; 2012 Nov; 56(4):e46. PubMed ID: 23361242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.
    Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z
    Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
    Wang Z; Zhu L; Guo T; Wang Y; Yang J
    Hum Pathol; 2015 Jul; 46(7):1006-14. PubMed ID: 25971547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma.
    Piao S; Liu Y; Hu J; Guo F; Ma J; Sun Y; Zhang B
    PLoS One; 2012; 7(8):e42540. PubMed ID: 22880026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma.
    Li J; Wang Z; Li Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1291-7. PubMed ID: 22447106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
    Zhang M; Wu W; Gao M; Fei Z
    Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
    Chen X; Jin J; Zheng L; Sheng Y; Sun J
    J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
    Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
    Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
    Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
    Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
    Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
    Xing Y; Luo DY; Long MY; Zeng SL; Li HH
    World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
    Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
    J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer.
    Hu J; Liu YL; Piao SL; Yang DD; Yang YM; Cai L
    Lung Cancer; 2012 Sep; 77(3):593-9. PubMed ID: 22717106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma.
    Zhibo Q; Lianxin L
    Adv Clin Exp Med; 2020 Mar; 29(3):295-300. PubMed ID: 32216173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.